Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32689303 | 1.00 | LIPC (0.32) | LIPCLIPG | |
| SCHEMBL29477779 | 1.00 | LIPC (0.32) | LIPCLIPG | |
| SCHEMBL25336690 | 0.97 | LIPC (0.31) | LIPCLIPG | |
| SCHEMBL25336684 | 0.97 | LIPC (0.31) | LIPCLIPG | |
| SCHEMBL25922186 | 0.93 | LIPC (0.33) | LIPCLIPG | |
| SCHEMBL25922177 | 0.93 | LIPC (0.33) | LIPCLIPG | |
| SCHEMBL25323037 | 0.92 | LIPC (0.32) | LIPCLIPG | |
| SCHEMBL25323034 | 0.92 | LIPC (0.32) | LIPCLIPG | |
| SCHEMBL32689233 | 0.91 | LIPC (0.33) | LIPCLIPG | |
| SCHEMBL24364903 | 0.91 | LIPC (0.33) | LIPCLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2023146989-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | LIPC 815/4885LIPG 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.